BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17440637)

  • 1. Molecule of the month: lisdexamfetamine mesilate.
    Drug News Perspect; 2007 Mar; 20(2):138. PubMed ID: 17440637
    [No Abstract]   [Full Text] [Related]  

  • 2. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attention deficit hyperactivity disorder in children.
    Ramchandani P; Joughin C; Zwi M
    Clin Evid; 2002 Jun; (7):262-71. PubMed ID: 12230649
    [No Abstract]   [Full Text] [Related]  

  • 4. Attention-deficit/hyperactivity disorder: the road traveled and the road ahead.
    Jun A
    Am J Health Syst Pharm; 2009 Nov; 66(22):2003. PubMed ID: 19890082
    [No Abstract]   [Full Text] [Related]  

  • 5. Lisdexamfetamine.
    Blick SK; Keating GM
    Paediatr Drugs; 2007; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lisdexamfetamine dimesylate.
    Elia J; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 May; 6(5):343-4. PubMed ID: 17539056
    [No Abstract]   [Full Text] [Related]  

  • 7. Attention deficit hyperactivity disorder in children.
    Ramchandani P; Joughin C; Zwi M
    Clin Evid; 2002 Dec; (8):280-90. PubMed ID: 12603883
    [No Abstract]   [Full Text] [Related]  

  • 8. Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults.
    Rostain AL
    Curr Psychiatry Rep; 2009 Oct; 11(5):341-2. PubMed ID: 19785973
    [No Abstract]   [Full Text] [Related]  

  • 9. Sex subgroup analysis of treatment response to lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder.
    McGough JJ; Greenbaum M; Adeyi B; Babcock T; Scheckner B; Dirks B; Findling RL
    J Clin Psychopharmacol; 2012 Feb; 32(1):138-40. PubMed ID: 22217951
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of attention-deficit-hyperactivity disorder.
    Elia J; Ambrosini PJ; Rapoport JL
    N Engl J Med; 1999 Mar; 340(10):780-8. PubMed ID: 10072414
    [No Abstract]   [Full Text] [Related]  

  • 11. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
    J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of stimulant drug treatment for hyperactivity: a meta-analysis.
    Kavale K
    J Learn Disabil; 1982 May; 15(5):280-9. PubMed ID: 6123539
    [No Abstract]   [Full Text] [Related]  

  • 13. An update on attention deficit disorder.
    Harv Ment Health Lett; 2004 May; 20(11):4-7. PubMed ID: 15153391
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Wigal T; Brams M; Gasior M; Gao J; Giblin J
    Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs: aliskiren hemifumarate, lisdexamfetamine dimesylate, and lapatinib.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(3):425-6, 428-30. PubMed ID: 17510042
    [No Abstract]   [Full Text] [Related]  

  • 17. A review of studies of drug treatment efficacy for attention deficit disorder with hyperactivity in adolescents.
    Varley CK
    Psychopharmacol Bull; 1985; 21(2):216-21. PubMed ID: 2860692
    [No Abstract]   [Full Text] [Related]  

  • 18. Methylphenidate versus dextroamphetamine in ADHD.
    Efron D
    J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):500. PubMed ID: 10230180
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
    Brams M; Giblin J; Gasior M; Gao J; Wigal T
    Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Attention deficit-hyperactivity disorder (ADHD); etiology, diagnosis and treatment].
    't Jong GW; van den Anker JN
    Ned Tijdschr Geneeskd; 2000 Nov; 144(46):2227-8. PubMed ID: 11103263
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.